A Trial To Assess Safety And Tolerability Of PF-04691502 In Cancer Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00927823
First received: June 23, 2009
Last updated: May 29, 2012
Last verified: May 2012
  Purpose

A phase 1 dose-escalation trial to assess the safety, tolerability, and pharmacodynamics of PF-04691502 in adult cancer patients with solid tumors.


Condition Intervention Phase
Cancer
Drug: PF-04691502
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1, Open-Label, Dose-Escalation Study To Evaluate Safety, Pharmacokinetics, And Pharmacodynamics Of The PI3K/MTOR Inhibitor PF-04691502 In Adult Patients With Advanced Malignant Solid Tumors

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Overall safety profile of PF-04691502 , including Dose Limiting Toxicities (DLTs) and Recommended Phase 2 Dose (RP2D) determination [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Single and multiple dose pharmacokinetic parameters of PF-04691502 [ Time Frame: 3 years ] [ Designated as safety issue: No ]
  • QTc interval [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
  • Changes in serum glucose and insulin after dosing with PF-04691502 [ Time Frame: 3 years ] [ Designated as safety issue: No ]
  • Changes in expression and/or phosphorylation of PI3K pathway proteins in biopsied tumor tissue [ Time Frame: 3 years ] [ Designated as safety issue: No ]
  • Genetic variations (mutation, deletion, amplification) in genes relating to PI3K pathway signaling such as PIK3CA and/or PTEN and/or Akt in biopsied tumor tissue [ Time Frame: 3 years ] [ Designated as safety issue: No ]
  • Objective tumor response using RECIST criteria [ Time Frame: 3 years ] [ Designated as safety issue: No ]
  • Changes in expression and/or phosphorylation of PI3K pathway proteins in biopsied hair follicles [ Time Frame: 3 years ] [ Designated as safety issue: No ]

Enrollment: 37
Study Start Date: December 2009
Study Completion Date: April 2012
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: PF-04691502 Treatment Drug: PF-04691502
Once daily continuous dosing. Dose escalation to Maximally tolerated dose (MTD) until progression or discontinuation.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with a histologically or cytologically confirmed malignant solid tumor for which there is no currently approved treatment or which is unresponsive to currently approved therapies.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1
  • Female patients of childbearing potential must have a negative serum or urine pregnancy test within 72 hours of the first dose of PF-04961502, These patients or their partners must be surgically sterile or be postmenopausal, or must agree to use effective contraception while receiving trial treatment and for at least 3 months thereafter. Male patients or their partners must be surgically sterile or must agree to use effective contraception while receiving trial treatment and for at least 3 months thereafter. The definition of effective contraception will be based on the judgment of the Principal Investigator or a designated associate
  • Adequate Bone Marrow Function, including:

    1. Absolute neutrophil count (ANC) ≥1500 cells/mm3
    2. Platelets ≥75,000 cells/mm3
    3. Hemoglobin ≥9 mg/dL
  • Adequate Renal Function, including:

SrCr <1.5 x ULN (upper limit of normal). OR Estimated creatinine clearance ≥60 mL/min, as calculated using method standard for the institution

  • Adequate Liver Function, including:

Bilirubin ≤1.5 x ULN AST (SGOT) ≤2.5 x ULN ALT (SGPT) ≤2.5 x ULN

  • Adequate glucose control, including no previous diagnosis of diabetes mellitus and HbA1c <7%.
  • Adequate Cardiac Function, including:

    12-Lead electrocardiogram (ECG) with normal tracing or non clinically significant changes that do not require medical intervention. QTc interval ≤470 msec and no history of Torsades des Pointes or other symptomatic QTc abnormality

Exclusion Criteria:

  • Patients with known active brain metastases. Patients with previously diagnosed brain metastases are eligible if they have completed their CNS treatment and have recovered from the acute effects of radiation therapy or surgery prior to the start of study medication, have discontinued corticosteroid treatment for these metastases for at least 4 weeks and are neurologically stable
  • Chemotherapy, radiotherapy (other than palliative radiotherapy to lesions that will not be followed for tumor assessment on this study, ie, non target lesions), biological or investigational agents within 2 weeks of Baseline disease assessments
  • Any surgery (not including minor procedures such as lymph node biopsy) within 4 weeks of Baseline disease assessments; or not fully recovered from any side effects of previous procedures
  • Prior therapy with an agent that is known or proposed to be active by action on PI3K and/or mTOR
  • Prior high-dose chemotherapy requiring hematopoetic stem cell transplantation within 12 months of study treatment start
  • Uncontrolled or significant cardiovascular disease:

A myocardial infarction within 12 months Uncontrolled angina within 6 months Congestive heart failure within 6 months. Diagnosed or suspected congenital long QT syndrome. Any history of ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes). Any history of second or third degree heart block (may be eligible if currently have a pacemaker) Heart rate <50/minute on pre-entry electrocardiogram Uncontrolled hypertension.

  • Current use or anticipated need for food or drugs that are known potent CYP3A4 inhibitors or inducers
  • Current use or anticipated need for food or drugs that are known potent CYP1A2 inhibitors or inducers
  • Concurrent administration of herbal preparations
  • Breast feeding: No studies have been conducted in humans to assess the impact of PF-04691502 on milk production, its presence in breast milk and its effects on the breast-fed child. Because drugs are commonly excreted in human milk and because of the potential for serious adverse reactions in nursing infants, lactating female patients are excluded from this study.
  • Any clinically significant gastrointestinal abnormalities, which may impair intake, transit or absorption of the study drug, such as the inability to take oral medication in tablet form and malabsorption syndrome.
  • Any mental disorder that would limit the understanding or rendering of informed consent and/or compromise compliance with the requirements of this protocol
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00927823

Locations
United States, California
Pfizer Investigational Site
Los Angeles, California, United States, 90404
Pfizer Investigational Site
Los Angeles, California, United States, 90095
Pfizer Investigational Site
Los Angeles, California, United States, 90095-6984
Pfizer Investigational Site
Santa Monica, California, United States, 90404
United States, Michigan
Pfizer Investigational Site
Detroit, Michigan, United States, 48201
United States, New York
Pfizer Investigational Site
Amherst, New York, United States, 14221
Pfizer Investigational Site
Buffalo, New York, United States, 14263
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00927823     History of Changes
Other Study ID Numbers: B1271001
Study First Received: June 23, 2009
Last Updated: May 29, 2012
Health Authority: United States: Food and Drug Administration

ClinicalTrials.gov processed this record on April 17, 2014